Teknova Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional ...
June 29 2021 - 7:00PM
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider
of critical reagents for the development and production of
biopharmaceutical products including drug therapies, novel
vaccines, and molecular diagnostics, today announced that on June
29, 2021, it closed its previously announced initial public
offering of 6,900,000 shares of its common stock, at a price to the
public of $16.00 per share. The closing included 900,000 shares
sold upon full exercise of the underwriters’ option to purchase
additional shares of common stock in the offering. All of the
shares of common stock were offered and sold by Teknova.
The aggregate gross proceeds to Teknova from the
offering, before deducting the underwriting discounts and
commissions and other offering expenses payable by Teknova, were
approximately $110.4 million. The shares began trading on the
Nasdaq Global Market on Friday, June 25, 2021, under the ticker
symbol “TKNO.”
Cowen and William Blair acted as joint
book-running managers for the offering. BTIG and Stephens Inc.
acted as co-managers. Paul Hastings LLP provided legal counsel to
Teknova and DLA Piper LLP (US) provided legal counsel to the
underwriters. Perella Weinberg Partners acted as capital markets
adviser to Teknova.
A registration statement on Form S-1 relating to
these securities was declared effective by the Securities and
Exchange Commission (“SEC”) on June 24, 2021. Copies of the
registration statement can be accessed by visiting the SEC’s
website at www.sec.gov. The offering was made only by means of a
prospectus. Copies of the final prospectus relating to the offering
may be obtained by contacting: Cowen and Company, LLC, c/o
Broadridge Financial Services, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood, NY 11717; or William Blair &
Company, LLC, Attention: Prospectus Department, 150 North Riverside
Plaza, Chicago, IL 60606. Electronic copies of the final prospectus
are also available on the SEC’s website at www.sec.gov.
This press release shall not constitute an offer
to sell, or a solicitation of an offer to buy, these securities,
nor shall there be any offer or sale of these securities in any
state or jurisdiction in which such offer, solicitation, or sale
would be unlawful prior to the registration or qualification under
the securities laws of any such state or jurisdiction.
About Teknova
Teknova is expediting clinical breakthroughs in
the life sciences by providing custom products and reagents for
bioprocessing, bioproduction, and molecular diagnostics. With a
focus on agility and customization, Teknova delivers research-grade
and GMP products including cell culture media and supplements,
protein and nucleic acid purification buffers, and molecular
biology reagents for a multitude of established and emerging
applications, including cell and gene therapy, mRNA therapeutics,
genomics, and synthetic biology. Teknova's proprietary processes
enable the manufacture and delivery of high quality, custom,
made-to-order products on short turnaround times and at scale
across all stages of development, including commercialization.
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-216-1830
Sara Michelmore
MacDougall
smichelmore@macbiocom.com
+1 781-235-3060
Media Contact
Matthew Corcoran
MacDougall
mcorcoran@macbiocom.com
+1 617-866-7350
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Sep 2023 to Sep 2024